Under the Biden administration proposal unveiled last November, an estimated 3.4 million Americans on Medicare would be eligible in 2026 for the drugs, which carry a list price of more than $1,000 a ...

CHICAGO, IL, USA I April 03, 2025 I Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago focused on the ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

For a variety of reasons, Globe Food contributor Kara Baskin took the leap and started Zepbound. But first she worried: "What ...

The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College ...

Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...

After about a year of limited progress, Makowicki’s physician recommended she start on Mounjaro, a glucagon-like peptide-1 agonist, commonly known as a GLP-1. The results were unlike anything ...

Tirzepatide acts on two targets — GLP-1 (glucagon-like peptide-1 ... granted to Eli Lilly for importing and marketing the medicine in a single dose pre-filled pen and in a single-dose vial in June ...

Ozempic (semaglutide) is a brand-name injection pen used to treat type 2 diabetes ... it is a type of drug called a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 ...

Mounjaro is a prescription medicine available as a pre-filled single-dose pen in 2.5 mg, 5 mg ... designed to bind to glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 ...

Ozempic (semaglutide) is a brand-name injection pen used to treat type 2 diabetes ... dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.